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Abstract 
Background: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a widely used instrument to assess 
Health-related Quality of Life (HRQoL) among inflammatory bowel disease (IBD) patients. Our aim was to translate and 
adapt the SIBDQ so that it could be adequately used in Portugal.
Methods: This is a prospective design cohort study undertaken at a tertiary hospital. This study took place simul-
taneously with the first part of the SexIDI study, a study aiming to assess the impact of IBD on patients’ sexual QoL. 
The original SIBDQ was translated by two independent translators and adapted by an IBD expert panel following the 
opinions of a convenient sample of 5 IBD patients. Afterwards, IBD patients from the outpatient clinic were consecu-
tively invited to fill the Portuguese version of the questionnaire (SIBDQ-PT) at three different timepoints (0, 2, 4 weeks). 
Ninety-two patients completed the SIBDQ-PT at baseline, whereas 33 did so after 2 and 4 weeks (approximately). 
Statistical analysis was performed using SPSS version 25, and the following aspects were analysed: reliability (through 
internal consistency, test–retest and intraclass correlation), validity (through exploratory factor analysis [EFA], and Pear-
son correlation coefficient for linear correlations), score distribution, and responsiveness analysis (through t-student 
tests).
Results: Overall, SIBDQ-PT was shown to have a high internal consistency (Cronbach’s α = 0.80) and a high test–
retest reliability (0.80 [CI 0.74–0.86] and 0.69 [CI 0.50–0.82]). EFA detected four dimensions—bowel, social, emotional 
and systemic. As expected, an overall SIBDQ-PT score was positively correlated with sexual satisfaction (r = 0.27; 
p < 0.05) and negatively correlated with depression (r = − 0.63; p < 0.01). Moreover, SIBDQ-PT was found to have 
an adequate score distribution, and to be responsive, as there was a significant subscore change for patients who 
reported an “overall worsening in general well-being” (0.93 ± 0.13 decrease; p < 0.01).
Conclusions: The Portuguese version of the SIBDQ hereby presented is a reliable, valid and responsive instrument 
that can be used to measure HRQoL among Portuguese IBD patients.
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Background
Inflammatory bowel diseases (IBD) are a group of chronic 
diseases characterised by an early onset and by a relapse 
and remission pattern. Prevalence has increased over 
time, mostly due to the low mortality rates associated 
with these conditions [1]. Prevalence estimates in Por-
tugal are, currently, among the highest in Europe [2, 3]. 
The unpredictable onset of disease flares, the associated 
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symptoms and the effects of treatment regimens strongly 
impact patients’ health-related quality of life (HRQoL) 
and, therefore, this is currently acknowledged as an 
important patient-reported outcome in IBD [4].
Chen et  al. recently conducted a critical review of 
HRQoL instruments specifically designed for IBD 
patients [5]. Among the many assessment tools, the IBD 
Questionnaire, developed by Guyatt et  al., was consid-
ered to be among the most suitable, valid and reliable. 
Irvine and colleagues validated a short, self-adminis-
tered version of the IBD Questionnaire, which was also 
found to be valid and reliable in assessing the HRQoL of 
Crohn’s disease (CD) and ulcerative colitis (UC) patients’ 
[5–7]. This Short Inflammatory Bowel Disease Ques-
tionnaire (SIBDQ) version became widely known and is 
currently used worldwide both in clinical practice and 
clinical research. The SIBDQ comprises a total of 10 
questions grouped into four different dimensions: social, 
bowel, emotional, and systemic [6, 7]. Each question is 
scored by a 7-point Likert scale, ranging from 1 (a severe 
problem) to 7 (not a problem at all), giving an absolute 
SIBDQ score ranging from 10 (poor HRQoL) to 70 (opti-
mal HRQoL). A SIBDQ score below 50 was considered 
as poor QoL. There are no validated cut-offs for the dif-
ferent dimensions’ scores. Hence, higher scores indicate a 
better HRQoL concerning that specific domain.
Although patient-reported outcomes are highly valu-
able for better patient care, patient responses to HRQoL 
instruments can be impacted by underlying cultural 
trends [8]. Therefore, the direct translation of HRQoL 
questionnaires does not guarantee their adequacy 
and utility in countries others than those in which the 
questionnaire was designed and initially validated. As 
stressed, the SIBDQ is among the best-characterised 
tools to access IBD HRQoL. Since its development, it has 
been increasingly used in observational studies, clinical 
trial and clinical practice settings. However, a Portuguese 
translation and validation of the SIBDQ was yet to be 
performed.
This article describes the adaptation and validation of 
the Portuguese version of the SIBDQ (SIBDQ-PT). Our 
aim was to adapt an international instrument so that it 
could effectively and adequately evaluate HRQoL among 
IBD patients in Portugal.
Materials and methods
SIBDQ translation and adaptation
The original version was independently translated 
forward (into Portuguese) by two bilingual transla-
tors (J.R., H.T.S.). The translations were reconciled to 
address discrepancies between the original forward 
independent translations. A single literal back transla-
tion (to English) was then performed by a Portuguese 
gastroenterology resident (J.R) who is a native language 
speaker with certified English proficiency. The original 
version and the back-translated version of the SIBDQ 
were compared and harmonised to ensure conceptual 
equivalence between the source and target language 
versions (J.R., H.T.S.). Moreover, a convenient sample 
of 5 Portuguese IBD patients evaluated the question-
naire in terms of interpretation/ease of comprehension 
and made their suggestions for improvement. Finally, 
a panel discussion with the project manager (J.R.) and 
bilingual experts in IBD (H.T.S. and F.M.) took place 
to check the final translation and to reformulate some 
items according to the cognitive debriefing of the 5 
patients.
Validation of the SIBDQ‑PT
This study took place simultaneously with the first part of 
the SexIDI study, a cross-sectional study aiming to assess 
the impact of IBD on patients’ sexual QoL [9]. Patients 
attending the IBD outpatient clinic of Portimão Hospi-
tal with 18 to 65  years of age and an IBD diagnosis for 
at least 2  years, were considered eligible. The Portimão 
Hospital is part of the Algarve Hospital University Center 
that includes the “Portimão unit” and the “Faro unit”. This 
is a general, tertiary care, public Hospital center; the Por-
timão unit provides care to approximately 500 gastroen-
terology outpatients monthly (according to January to 
March 2019 hospital statistics). Two clinicians (J.R. and 
H.T.S.) conducted eligibility assessments and invited 
patients to participate in the study. One hundred, con-
secutive patients were invited to participate between July 
and December 2016. Patients willing and able to partici-
pate signed an informed consent form prior to inclusion.
At baseline, patients were given a multimodal form 
including not only the SIBDQ-PT, but also questions 
regarding socio-demographic variables (age, sex, nation-
ality, educational level, professional status, relationship 
status), clinical variables (height and weight, type of IBD 
and disease duration), and three already validated scores: 
(1) the short version of the Social Desirability Scale 
(SDS-SF) [10], which measures the tendency to engage 
in socially desirable responding; (2) the Sexual Quality of 
life questionnaire Male/Female (SQol M/F) [11], which 
focuses on patients’ feelings about their sexual life; and 
(3) the Nine-item Patient Health Questionnaire (PHQ-9) 
[12], which is a depression spectrum disorder symptom 
scale. The SIBDQ-PT was later applied in two other time-
points, approximately 2 and 4  weeks after baseline, and 
at the last timepoint patients were also questioned about 
whether they felt an “overall worsening in their general 
well-being”. In all cases the questionnaires were anony-
mous and self-administered.
Page 3 of 9Roseira et al. Health Qual Life Outcomes           (2021) 19:59  
Statistical analysis
Acceptability
The acceptability of the SIBDQ-PT was determined 
according to the degree to which the questionnaires were 
filled. Whenever more than 20% of answers were missing 
from a questionnaire, that questionnaire was excluded 
from the analysis. The average time to complete the 
questionnaire was auto-assessed for the initial 5-patient 
sample.
Item reduction and data structure
Exploratory Factor Analysis (EFA) with Principal Com-
ponents (PC) Extraction method was used to detect 
the underlying structure of the 10 items included in the 
SIBDQ-PT, and to confirm the multidimensionality of 
the questionnaire previously determined by Irvine et  al. 
[6, 7] Kaiser–Meyer–Olkin measure (KMO) of adequacy 
and Bartlett’s test of sphericity were directed to check 
sample adequacy for carrying out an EFA [13]. The num-
ber of factors was set using the Kaiser rule (latent roots 
equal or greater than one) computed from the correla-
tion matrix of all original items. The determinant of the 
matrix was used to test for multicollinearity or singular-
ity (the determinant should be greater than 0.00001). A 
Varimax orthogonal rotation was performed. The rota-
tion has the effect of optimizing the factor structure and 
equalizing relative importance of factors. An orthogonal 
rotation was preferred to maintain the assumption of the 
orthogonality of the dimensions, and to allow the results 
to have the greatest possible independence of the axis 
formed by the new linear combinations of the original 
variables. The number of components was set by exam-
ining the plot of eigenvalues [14]. The final components 
were supported according to the total variance explained 
and the solution interpretability. Finally, the communali-
ties reflected the common variance of the data structure.
Reliability
Reliability (the extent to which scores tend to remain 
the same for a patient under the same conditions) was 
measured using all items from the health-related patient-
reported outcome (HrPRO) (internal consistency), and 
over time (test–retest) [15].
Internal consistency was assessed using Cronbach’s α 
(employs covariances among the items) and Cronbach’s 
α based on standardized items (employs the correlations 
among items). Cronbach’s α 0.7–0.9 corresponds to an 
adequate homogeneity of the items [16].
Test–retest reliability was assessed using the intraclass 
correlation coefficient (ICC) [15] between the results 
obtained in the two initial timepoints. An interval of two 
weeks was considered long enough to prevent recall-bias 
and short enough to ensure similar disease status. ICC 
was calculated on the basis of an absolute agreement and 
the 95% confidence intervals (CIs) were verified [17]. An 
ICC 0.60–0.75 is classified as “good” [18]. The standard 





Validity refers to the degree to which a HrPRO meas-
ures the variable it is meant to. Structural validity was 
assessed through the above mentioned EFA and con-
struct validity was evaluated using the hypothesis testing 
method [15, 19]. Pearson’s correlations between SIBDQ-
PT/SQoL and SIBDQ-PT/PHQ-9 administered at base-
line were calculated. The following hypotheses were a 
priori formulated: (1) the SIBDQ-PT overall score posi-
tively correlates with sexual QoL (SQoL); (2) the SIBDQ 
overall score negatively correlates with depression symp-
toms (PHQ-9). A Pearson’s correlation coefficient 0.3–0.5 
is classified as “fair”, between 0.5 and 0.8 as “moderately 
strong”, and greater than 0.8 as “very strong” [20].
Score distribution
Score distribution or measurement bias refers to the dis-
tribution of the scores in the entire sample, taking into 
account deviations such as floor and ceiling effects [15, 
19]. These effects are considered to be offending if more 
than 15% of the patients have the minimum or the maxi-
mum score.
Responsiveness
Responsiveness refers to the sensitivity to change of 
the questionnaire [15]. The Student’s t-test for paired 
measurements was used to compare the mean scores 
for SIBDQ-PT individual items between baseline and 
the third timepoint for patients who referred an “overall 
worsening in general well-being”. Individual items scores 
were also compared for those who did not perceive dis-
ease worsening.
Observed data was described as mean ± standard devi-
ation for continuous variables and absolute and relative 
frequencies for categorical variables. All statistical analy-
ses were performed using SPSS version 25.0 (IBM Corp., 
Armonk, New York, USA), and level of significance of 5% 
was established.
Results
SIBDQ translation and cultural adaptation
Translation and cultural adaptation of the SIBDQ fol-
lowed a multiphase process: forward translation, recon-
ciliation, back translation, review and harmonization, 
comprehensibility assessment by an IBD sample of 
5 patients, a panel consensus meeting to review the 
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cognitive debriefing results from the 5-patient sample, 
and finally proofread the translated scale. Minor discrep-
ancies during the forward and back translation phases 
included the use of prepositions and sentence structure. 
Additionally, one unresolvable problem was identified 
and clarified after the final panel discussion: for items 
6 and 7, the first Likert-scale response option “a major 
problem”, could be translated to “problema major” or 
“problema severo” that can be used synonymously in 
Portuguese. The first solution was chosen for its similar-
ity to the original English scale. Finally, the expert IBD 
panel reviewed the SIBDQ-PT translation and the ques-
tions raised by the initial sample of 5 patients and made 
three main adaptations to the Portuguese version of the 
SIBDQ:
1. Item 3—“how much difficulty” was changed to 
“quantify the difficulty” (“quantifique a dificuldade” in 
Portuguese), in order to obtain a more grammatically 
appropriate translation.
2. Item 7—The interpretation of the expression “weight 
you would like to be” raised some doubts, as all five 
patients that evaluated the questionnaire reported 
they would like to weigh less than what they 
acknowledge would be their ideal weight. Therefore, 
the term was changed to “ideal weight” (“peso ideal” 
in Portuguese), meaning the ideal weight before the 
modifications imposed by the disease.
3. Item 8—This item addresses the frequency with 
which patients have been feeling relaxed, and the 
7-point Likert scale in the original version was organ-
ized from 1 (“none of the time”) to 7 (“all of the 
time”). However, throughout the rest of the question-
naire (namely items 1, 2, 4, 5, 9 and 10), the 7-point 
Likert scale is organized from 1 (“all of the time”) to 
7 (“none of the time”). Therefore, 3 of the 5 patients 
from the initial sample reported an initial impulse to 
answer as if options were also sequenced from “all 
of the time” to “none of the time”. Accordingly, the 
answers to question number eight in the SIBDQ-PT 
were reorganised to follow the same sequence as the 
answers to the other questions.
Sociodemographic, clinical data and score results
At baseline, 92 of the 100 patients who were invited 
accepted to participate in this study and fulfilled the mul-
timodal questionnaire at first timepoint (i.e. baseline), 
whereas only 33 (35.87%) were available to do so in the 
second and third timepoints. The sociodemographic and 
clinical characteristics of the study population are shown 
in Table 1. Patients were mostly female (57.61%), tended 
to be middle-aged (40–49  years, 31.52%), employed 
(76.09%), married (45.65%), and had mostly completed 
high-school (52.17%). No major differences were found 
between age ranges [(18–39  years old; n = 42, 45.65%); 
(40–65  years old; n = 50, 54.35%)] and gender [(female; 
n = 53, 57.61%); (male; n = 39, 42.39%)]. Age and gender 
were also comparable in the sample of participants who 
completed the study questionnaires in the subsequent 
timepoints (Table 1). On the other hand, the sample com-
prised patients with somewhat different educational lev-
els, working status and relationships. Overall, 38 (41.30%) 
patients had CD and 54 (58.70%) had UC, and the median 
disease duration was 5  years (interquartile range 15.5). 
The mean ± standard-deviation of the SIBDQ-PT score 
obtained at baseline was 52.80 ± 9.45, with a median 
score of 54.00. The median scores for the SDS-FS, SQoL 
and PHQ-9 scales, also fulfilled at baseline, were ana-
lysed separately for patients that scored below or above 
the median SIBDQ-PT (Table  2). The mean ± standard-
deviation of the SIBDQ-PT score obtained at the second 




The 5 patients who initially evaluated the SIBDQ-PT 
reported to have spent an average of 3 min to complete 
the questionnaire.
In terms of the multimodal questionnaire administered 
at baseline, all patients completed the SIBDQ-PT and the 
PHQ-9 scores. However, 3.26% of patients did not com-
plete the SDS-SF score (two questionnaires had over 80% 
of missing values and were, therefore, excluded from the 
analysis), and 14.13% of patients did not complete the 
SQoL questionnaire (but no questionnaire had over 80% 
of missing values, and therefore all completed question-
naires were included in the analysis). As for the second 
and third timepoints, all patients completed the SIBDQ-
PT questionnaire.
Item reduction and data structure
The correlation matrix was used to verify the pattern to 
be observed between the 10 items that composed the 
SIBDQ-PT: the correlation coefficients were no greater 
than 0.9 and the determinant of the correlation matrix 
was 0.02 which is greater than the necessary value of 
0.00001. Thus, singularity and multicollinearity of the 
data were excluded, and there was no need to consider 
eliminating any item of the questionnaire.
Eigenvalues above one allowed to reduce the initial 
data dimension to three factors, explaining over 60% of 
questionnaire variance. However, due to the fourth eigen-
value proximity to one (0.933), and because it translated 
into an accumulated contribution of variance of 74.49%, 
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a four-factor solution was considered. The Pearson cor-
relation coefficients between the items and the factors 
are shown in Table  3. Factor one is expressed by items 
4, 6, 9 and 10; factor two is expressed by items 2, 3 and 
5; factor three is expressed by items 1 and 8; factor four 
in expressed by item 7. Keeping the terminology used in 
the original questionnaire, the four factors detected in 
the SIBDQ-PT were named as the bowel dimension, the 
social dimension, the emotional dimension and the sys-
temic dimension.
The sample adequacy was supported by a KMO > 0.79 
(meritorious) and a Bartlett’s Test of Sphericity p 
Table 1 Sociodemographic and clinical characteristics
SD standard deviation
Variables Baseline sample Second and third 
timepoints 
sample
(n = 92) (n = 33)
Age, n (%)
 [18–20] 3 (3.26) 2 (6.06)
 [21–29] 21 (22.83) 6 (18.18)
 [30–39] 18 (19.57) 11 (33.33)
 [40–49] 29 (31.52) 9 (27.27)
 [50–59] 15 (16.30) 4 (12.12)
 > 60 6 (6.52) 1 (3.03)
Sex, n (%)
 Female 53 (57.61) 17 (51.52)
 Male 39 (42.39) 16 (48.48)
Anthropometric data, mean ± SD
 Weight 68.97 ± 14.23 69.30 ± 13.41
 Height 167.69 ± 9.99 167.97 ± 9.81
Educational status, n (%)
 Primary schooling 15 (16.30) 4 (12.12)
 High schooling 48 (52.17) 18 (54.55)
 Graduation degree 27 (29.35) 10 (30.30)
 Master’s degree 2 (2.17) 1 (3.03)
Current professional status, n (%)
 Employed 70 (76.09) 21 (63.64)
 Unemployed, looking for a job 11 (11.96) 7 (21.21)
 Unemployed, not looking for a job 2 (2.17) 2 (6.06)
 Retired 7 (7.61) 2 (6.06)
 Temporary disability 2 (2.17) 1 (3.03)
Marital status, n (%)
 Married 42 (45.65) 14 (42.42)
 Divorced 14 (15.30) 4 (12.12)
 Single/dating 36 (39.13) 15 (45.45)
Type of IBD, n (%)
 Crohn’s disease 38 (41.30) 14 (42.42)
 Ulcerative colitis 54 (58.70) 19 (57.58)
 Duration of the disease, median (range) 5.00 (2–40) 5.00 (3–40)
Table 2 Median baseline scores and  standard deviation 
for the SDS-FS, SQoL and PHQ-9 according to the median 
SIBDQ-PT
SIBDQ-PT Portuguese version of the Short Inflammatory Bowel Disease 
Questionnaire, SDS-FS short version of the Social Desirability Scale, PHQ-9 the 








SIBDQ-PT < 54 10.00 ± 2.09 57.57 ± 21.48 6.00 ± 4.88
SIBDQ-PT ≥ 54 10.00 ± 1.64 83.33 ± 17.23 2.00 ± 3.06
Difference 0.00 25.76 4.00
p value 0.92 0.01 0.00
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value < 0.01. The communalities values of each item 
ranged between 0.58 (item 6) and 0.84 (item 8).
Reliability
The SIBDQ-PT Cronbach’s α coefficient was 0.80, which 
indicates an adequate homogeneity of the items. More-
over, the test–retest reliability was high, as indicated by 
the ICC between the baseline and the second SIBDQ-PT 
administration: 0.69 (95% CI: 0.50–0.82). Considering 
the SIBDQ-PT retest and reliability results, the estimated 
standard error was 4.43.
Validity
We have a priori hypothesised that the SIBDQ-PT should 
be positively correlated to sexual QoL and negatively cor-
related with the incidence of depressive symptomatol-
ogy. These hypotheses held true, as an overall SIBDQ-PT 
score was found to be positively correlated with sexual 
satisfaction (r = 0.27; p < 0.05) and negatively correlated 
with depression symptoms (r = − 0.63; p < 0.01).
Score distribution
The floor and ceiling effects detected in the test and retest 
(second timepoint) were considered to be irrelevant. At 
baseline, only two and one patients had an overall score 
at the lower and upper end of the scale, respectively. At 
the retest, one patient had an overall score at the lower 
end of the scale, and one other patient had a score at the 
upper end of the scale.
Responsiveness
Out of the 33 patients who completed the SIBDQ-PT 
on the third timepoint (30 to 43  days after baseline), 9 
patients reported an “overall worsening in their general 
well-being”: their individual items mean scores (range 
1–7) were statistically significantly lower than at baseline: 
5.63 vs. 4.70 (0.93 ± 0.13 decrease; p < 0.01). For those 
who did not perceive disease worsening (n = 24), indi-
vidual scores remained comparable (0.01 ± 0.03 decrease: 
p = 0.08).
Discussion
The importance of patient-reported outcomes, namely in 
what concerns HRQoL, is increasingly acknowledged as a 
key aspect in the management of IBD patients. HRQoL is 
a multidimensional concept that can be viewed as a latent 
construct encompassing physical, social and psychologi-
cal aspects of well-being and role functioning [21]. But 
despite the far-reaching nature of this definition, the 
importance of using culturally-validated instruments in 
local language is often ignored. Consequently, the qual-
ity of psychometric data falls behind that of the somatic 
data. With this study we aimed to translate and validate 
the widely used SIBDQ so that it could be adequately 
used in Portugal.
Eight translations of the original IBDQ have been vali-
dated in Europe, as well as two translations of the SIBDQ 
[22–31]. No IBDQ nor SIBDQ translations have, to the 
best of our knowledge, been validated in Portugal. Some 
reviews do refer to a Portuguese validation of the IBDQ, 
but this validation was made in the Brazilian context [32].
After independent forward and backward translations, 
context-validation by an IBD cohort, and an expert panel 
meeting, we have translated the SIBDQ to Portuguese 
(SIBDQ-PT). Also, as a result of this study the SIBDQ-
PT was found to be structurally valid, reliable, convergent 
with sexual satisfaction and depression, to have an appro-
priate score distribution and to be responsive to change. 
In order to assess the psychometric data of the SIBDQ-
PT, we have applied the questionnaire at three different 
timepoints separated by a two-week interval. The base-
line questionnaire was self-administered to a panel of 
92 IBD outpatients accounting for 92% of invited indi-
viduals. This panel size was considered to be appropriate, 
having into account that the original SIBDQ comprises a 
total of 10 items and the minimum patient-to-item ratio 
recommended to run a factor analysis is 7:1 [19]. Regard-
ing the second and third timepoints, and despite the fact 
that all 92 patients were invited to participate, only 33 
were available to do so. Still, the sample size was appro-
priate to check the parameters that depended on the rep-
etition of the questionnaire (re-test and responsiveness 
analysis).
The SIBDQ-PT construct validity was demonstrated 
through the confirmation of the a priori formulated 
hypotheses: an overall SIBDQ-PT score was positively 
correlated with sexual QoL (SQoL) and negatively cor-
related with depression symptoms (PHQ-9). The study 










Item 1 0.39 0.34 0.56 0.18
Item 2 0.23 0.66 0.01 0.54
Item 3 0.11 0.83 -0.02 0.12
Item 4 0.81 0.30 0.15 -0.03
Item 5 0.45 0.55 0.45 -0.25
Item 6 0.47 0.37 0.37 0.27
Item 7 0.16 0.12 0.13 0.86
Item 8 0.04 0.11 -0.90 -0.07
Item 9 0.82 -0.10 0.04 0.27
Item 10 0.75 0.36 -0.02 0.17
Extraction method: principal component analysis;
Rotation method: Varimax with Kaiser Normalization; rotation converged in 7 
iterations
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conducted in the context of the British translation [28] 
unveiled the presence of a strong correlation between the 
HRQoL, measured by the SIBDQ, and physician-evalu-
ated disease activity indexes namely the Simple Clinical 
Colitis Activity index (SCCAI) and the Seo index: r = 0.83 
(p < 0.01) for the SCCAI and r = 0.61 (p < 0.01) for the 
Seo index. However, the original American SIBDQ [6, 7] 
acknowledges the existence of psychosocial dimensions 
other than the “bowel dimension”. Moreover, IBD-focused 
studies have shown that the patient self-perception of the 
illness is a better predictor of QoL, than IBD activity [33–
35]. Thus, this study aimed to be fully based on patient-
reports. We have, therefore, investigated the presence of 
correlations between HRQoL and other patient-reported 
concerns/symptoms like sexual QoL and depression, and 
identified a fair and a strong correlation, respectively. 
Sexual QoL may be a very different construct which is 
related to IBD-specific HRQoL but only distally, account-
ing for the fair correlation. Depression on the other hand, 
seems to be a measure better fitting this “patient percep-
tion of the illness” umbrella to test convergent validity 
of the SIBDQ. Construct validity was validated by the 
hypothesis testing method [19] using only patients self-
rated measures.
The results of the EFA analysis confirmed that the 
SIBDQ-PT measures different components of QoL. 
Similarly to what is observed in the original version [6, 
7], four dimensions—bowel (expressed by items 4, 6, 9 
and 10), social (expressed by items 2, 3 and 5), emotional 
(expressed by items 1 and 8) and systemic (expressed by 
item 7)—were perceived in the Portuguese version of the 
SIBDQ. However, if we compare the original version and 
the Portuguese version (see Additional file 1), we notice 
that these dimensions were not expressed exactly by the 
same items. Item 10, for example, refers to the time dur-
ing which the patient “felt angry as a result of his/her 
bowel problem”. In the original American SIBDQ this 
item is included in the emotional dimension, whether in 
the Portuguese version it is included in the bowel dimen-
sion. This question refers to “anger” related to the “bowel 
problem”, thus it adequately expresses both dimensions 
depending on the tone we put on the emotion and on the 
bowel condition. This is highly influenced by patients’ 
interpretations in different contexts, according to their 
language and population structure, and further reinforces 
the importance of using language-validated instruments. 
Items one and 5, referring to “exhaustion” and “demotiva-
tion”, also express different dimensions comparing both 
SIBDQ (systemic and emotional) and SIBDQ-PT (emo-
tional and social), and a similar explanation applies. As 
so, we believe our four-dimension solution is not only 
supported by the total variance explained (over 70%), 
but also by its interpretability. As for the dimensions’ 
individual scores, alike the original SIBDQ there are no 
validated cut-offs. Hence, higher scores indicate a better 
HRQoL concerning that specific domain.
SIBDQ-PT was shown to have high internal consist-
ency and test–retest reliability. The assessment of the 
score distribution included the evaluation of SIBDQ-PT 
total scores and the assessment of floor/ceiling effects, 
which were absent both at baseline and on the re-test. 
Sensitivity to change was stressed by the responsiveness 
analysis for patients who self-reported an overall worsen-
ing in their condition.
This study has several strengths that should be high-
lighted. Since the only criteria for participation in this 
study was age 18–65 years and a diagnosis for at least two 
years, the study population was community-based and, 
therefore, likely representative of all stages of the disease. 
As people tend to differ in their tendency to engage in 
socially desirable responding (SDR), which is a concern 
when analysing self-administered questionnaires, a SDR 
questionnaire—the SDS-FS [10]—was administered in 
parallel with the SIBDQ-PT. Additionally, and despite 
the absence of heterogeneity in terms of age and gender 
distribution, the sample included patients with different 
educational levels and working/relationship status, and 
was therefore considered to be adequate for a cultural 
adaptation and validation [5]. To our knowledge, this 
is the first study evaluating the score distribution and 
measurement bias of SIBDQ—neither the original ver-
sion developers nor the authors of the British and Ger-
man translations assessed this aspect [28, 29]. Another 
important strength is the fact that the questionnaire was 
self-administered, ensuring patients were given the same 
instructions and the instrument was fulfilled under the 
same conditions. Data collection in other translation vali-
dations is performed over the phone and with different 
interviewers, which may influence the results. Neverthe-
less, this study also has limitations that should be noted. 
The study was conducted at a single centre, the sample 
is modest and recruited by convenience. Still this sample 
is assumed to be representative of the Portuguese popu-
lation for the purposes of this translation, allowing ade-
quate and complete psychometric assessment.
Conclusions
Assessing HRQoL in an objective and reliable way is now 
considered to be a prerequisite of well-designed IBD tri-
als. Therefore, careful validation of the SIBDQ in differ-
ent languages is an essential step to allow the comparison 
of data across different countries in multinational trials. 
As a result of this study, we now have a validated Portu-
guese version of the SIBDQ available for use in both clin-
ical practice and clinical trials (Additional file 1).
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